Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Brain Neoplasms: full-pipeline trial registry
8 of 15 indexed Brain Neoplasms trials are currently recruiting.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 8 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Brain Neoplasms: 15 US clinical trials tracked, 8 recruiting.
Brain Neoplasms is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is University of Utah, running 2 of these trials.
Enrollment posture brief
Registry condition brain-neoplasms
OPEN 8 | RECR 53% | LATE 3 | EARLY 4 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Beta-Thalassemia (53% recruiting · 15 trials)
Brain Neoplasms lists 8 open slots (53% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Brain Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Brain Neoplasms is recruiting above its size-band peers.
8 of 15 indexed trials (53.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Brain Neoplasms trials is spread across many organizations.
University of Utah accounts for 2 of 15 trials (13.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Brain Neoplasms enrolment sits around 125 participants.
Median target enrolment is 125 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.
-
Brain Neoplasms research is mostly interventional.
11 interventional and 4 observational studies make up this index (73.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Jasper Gerritsen
NCT06118723
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
NCT06273176
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Dartmouth-Hitchcock Medical Center
NCT06930846
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Stemline Therapeutics
NCT05386108
Guided Meditation During Radiation Therapy for Brain Tumors
University of Utah
NCT06165653
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
Mayo Clinic
NCT06322602
Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery
University of Illinois at Chicago
NCT07111182
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
Telix Pharmaceuticals (Innovations) Pty Limited
NCT07238322
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Bristol-Myers Squibb
NCT02667587
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
Pharmacyclics
NCT00054795
Hypovitaminosis D in Neurocritical Patients
University of Utah
NCT02881957
Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00075166
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
AbbVie (prior sponsor, Abbott)
NCT00649207
(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
National Cancer Institute (NCI)
NCT00001807
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Brain Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Brain Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Brain Neoplasms page
15 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Brain Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Utah sponsors the most Brain Neoplasms trials on record, review their full trial history before evaluating a specific study. See University of Utah's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Neoplasms condition card totals 15 registered trials; most-linked intervention Whole Brain Radiation Therapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.